Highbridge Capital Management’s AstraZeneca AZN Stock Holding History

Highbridge Capital Management’s Portfolio AZN Stock Details AZN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q3	–	Sell	-110,000	Closed	-$7.5M	–	1523
2017 Q2	$7.5M	Buy	+110,000	New	+$7.18M	0.11%	230
2016 Q3	–	Sell	-50,000	Closed	-$3.02M	–	1311
2016 Q2	$3.02M	Buy	+50,000	New	+$2.9M	0.05%	349

Other funds holding AZN

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Fisher Asset Management Camas, Washington $295B AUM 31.6% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Highbridge Capital Management's AZN Position: Q2 2018 in Review

Highbridge Capital Management sold out of AstraZeneca (AZN) in Q2 2018, closing a stake of 7,500 shares — an estimated $525K sold.

Highbridge Capital Management first reported a position in AZN in Q2 2016 and held it in 3 quarters. The position peaked at $8.44M in Q2 2016. 531 funds tracked by Wall St. Rank hold AZN as of Q2 2018.

Highbridge Capital Management reported no remaining AstraZeneca position as of Q2 2018 after selling out during the quarter.
Highbridge Capital Management sold 7,500 AstraZeneca shares in Q2 2018, an estimated $525K.
Highbridge Capital Management first reported a position in AstraZeneca in Q2 2016 and held it in 3 quarters.
Highbridge Capital Management's AstraZeneca position peaked at $8.44M in Q2 2016.
531 funds tracked by Wall St. Rank held AstraZeneca as of Q2 2018.

Based on Highbridge Capital Management's 13F filing for Q2 2018, filed 14 Aug 2018.